Mesothelioma Biopsy Procedures - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned refs (RON-2026-04-05-003)

2026-04-06T10:12:17Z

Fix structural reference errors: remove orphaned refs (RON-2026-04-05-003)

MesotheliomaSupport: Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

2026-03-08T22:37:28Z

Add differentiated triple GEO format: At-a-Glance, Key Facts wikitable, FAQ, Quick Statistics, Get Help

Show changes

MesotheliomaSupport: Remove H1, convert exec summary to lead, add listicle

2026-02-24T06:41:08Z

Remove H1, convert exec summary to lead, add listicle

← Older revision		Revision as of 06:41, 24 February 2026
Line 8:		Line 8:
	{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Biopsy Procedures		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Biopsy Procedures
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Tissue Diagnosis for Mesothelioma		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Tissue Diagnosis for Mesothelioma
Line 39:		Line 39:
	\|}		\|}

	= ~~Mesothelioma Biopsy Procedures: How Tissue Diagnosis Confirms Mesothelioma~~ and ~~Guides Treatment~~ =		A '''tissue biopsy''' remains the only definitive method for confirming a mesothelioma diagnosis, as no combination of imaging modalities can distinguish malignant pleural mesothelioma from metastatic pleural disease or benign pleural conditions with sufficient certainty to guide treatment decisions. '''CT scanning''' achieves only '''68% sensitivity''' and '''78% specificity''' for pleural malignancy, while '''PET-CT''' improves sensitivity to approximately 95% but produces false positives from inflammatory conditions such as tuberculous pleurisy and prior talc pleurodesis.<ref name="pmc_clinical_diagnosis" /><ref name="pmc_diagnostic_approach" /> Histological confirmation through biopsy is essential for determining the '''histological subtype''' (epithelioid, sarcomatoid, or biphasic), performing '''immunohistochemistry''' with standardized marker panels, conducting ancillary molecular testing including '''BAP1 loss''' and '''CDKN2A FISH''', and developing an evidence-based treatment plan that matches the individual patient's disease characteristics.<ref name="pmc_vats_accuracy" /><ref name="dandell_diagnosis" />

	~~== Executive Summary ==~~		'''Mesothelioma biopsy procedures at a glance:'''
			* '''~35% fluid cytology sensitivity''' — thoracentesis detects mesothelioma in only about 1 in 3 cases, falling to 6% in patients with asbestos exposure history<ref name="ats_contemporary" />
	~~A tissue~~ biopsy ~~remains the only definitive method for confirming~~ a mesothelioma diagnosis, as no combination of imaging modalities can distinguish malignant [[Pleural Mesothelioma\|pleural mesothelioma]] from metastatic pleural disease or benign pleural conditions with sufficient certainty to guide treatment decisions. CT scanning achieves only ~~68% sensitivity and 78% specificity for pleural malignancy~~, ~~while PET-CT improves sensitivity~~ to ~~approximately 95~~% ~~but produces false positives from inflammatory conditions such as tuberculous pleurisy and prior talc pleurodesis.~~<ref name="~~pmc_clinical_diagnosis~~" /><ref name="pmc_diagnostic_approach" /> ~~Histological confirmation through biopsy~~ is ~~essential for determining~~ the ~~histological subtype (epithelioid, sarcomatoid, or biphasic), performing immunohistochemistry~~ with ~~standardized marker panels, conducting ancillary molecular testing including BAP1 loss and CDKN2A FISH, and developing an evidence~~-~~based treatment plan that matches the individual patient's disease characteristics.~~<ref name="pmc_vats_accuracy" /><ref name="~~dandell_diagnosis~~" />		* '''93% CT-guided biopsy yield''' — core needle biopsy achieves high accuracy when targeting pleural thickening greater than 4 mm<ref name="pmc_diagnostic_approach" />
			* '''93-95% VATS sensitivity''' — video-assisted thoracoscopic surgery is the gold-standard diagnostic procedure with near-perfect specificity<ref name="pmc_vats_accuracy" />
	~~The diagnostic pathway for suspected mesothelioma involves a hierarchy of procedures ranging from minimally invasive fluid sampling to open surgical biopsy, each with distinct accuracy profiles~~ and ~~clinical indications. Thoracentesis with pleural fluid cytology serves as~~ the ~~initial screening step but achieves only approximately 35% sensitivity for mesothelioma~~, ~~significantly lower than for other pleural malignancies. CT~~-~~guided core needle biopsy provides 93% diagnostic yield when targeting visible pleural thickening~~, ~~while video-assisted thoracoscopic surgery~~ and ~~medical thoracoscopy represent the gold standard with sensitivity exceeding 93~~-~~95% and the ability to combine diagnostic biopsy with therapeutic fluid drainage and pleurodesis in a single procedure.~~<ref name="~~pmc_diagnostic_approach~~" /><ref name="~~pmc_vats_accuracy~~" /><ref name="~~mlc_diagnosis~~" />		* '''92% medical thoracoscopy yield''' — local-anesthesia thoracoscopy combines diagnosis, fluid drainage, and pleurodesis in one session<ref name="pmc_diagnostic_approach" />
			* '''2+ mesothelial and 2+ epithelial markers''' — the recommended IHC panel includes calretinin, WT1, MOC-31, and Ber-Ep4 at minimum<ref name="pmc_ihc_panel" />
	~~Accurate diagnosis requires adequate tissue sampling~~ — ~~concordance between biopsy and final surgical histology reaches 100~~% ~~when 10 or more tissue blocks are obtained — combined with a standardized immunohistochemistry panel of at least two mesothelial markers (calretinin~~, ~~WT1~~) ~~and two epithelial markers (MOC-31, Ber-Ep4), supplemented by BAP1 IHC and CDKN2A FISH for distinguishing malignant mesothelioma from benign mesothelial proliferations.~~<ref name="~~pmc_tissue_blocks~~" /><ref name="~~pmc_ihc_panel~~" /><ref name="~~mesonet_biopsy~~" />		* '''100% concordance at 10+ blocks''' — diagnostic accuracy between biopsy and surgical histology reaches perfection with adequate tissue sampling<ref name="pmc_tissue_blocks" />
			* '''4% needle tract seeding risk''' — image-guided core needle biopsy carries far lower seeding rates than surgical biopsy at 22%<ref name="pmc_bergamin_meta" />
			* '''SMART trial: no significant benefit''' — prophylactic radiotherapy did not significantly reduce tract metastases (9% vs. 16%, p=0.14) in 203 randomized patients<ref name="pmc_smart_trial" />
			* '''25% surgical plan change''' — laparoscopic staging of peritoneal mesothelioma alters the operative approach in 1 of 4 cases<ref name="jovs_thoracoscopy_staging" />
			* '''71% needle-to-surgical concordance''' — CT-guided biopsy subtyping accuracy is lower than thoracoscopy at 81.9%, reflecting smaller tissue volumes<ref name="pmc_tissue_blocks" />

	{\| class="wikitable" style="width:100%; border:2px solid #1a5276; margin:1em 0;"		{\| class="wikitable" style="width:100%; border:2px solid #1a5276; margin:1em 0;"

MesotheliomaSupport: Internal linking: added 2 wiki links

2026-02-20T21:01:33Z

Internal linking: added 2 wiki links

← Older revision		Revision as of 21:01, 20 February 2026
Line 8:		Line 8:
	{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:300px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Biopsy Procedures		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Biopsy Procedures
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Tissue Diagnosis for Mesothelioma		\| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" \| Tissue Diagnosis for Mesothelioma
Line 43:		Line 43:
	== Executive Summary ==		== Executive Summary ==

	A tissue biopsy remains the only definitive method for confirming a mesothelioma diagnosis, as no combination of imaging modalities can distinguish malignant pleural mesothelioma from metastatic pleural disease or benign pleural conditions with sufficient certainty to guide treatment decisions. CT scanning achieves only 68% sensitivity and 78% specificity for pleural malignancy, while PET-CT improves sensitivity to approximately 95% but produces false positives from inflammatory conditions such as tuberculous pleurisy and prior talc pleurodesis.<ref name="pmc_clinical_diagnosis" /><ref name="pmc_diagnostic_approach" /> Histological confirmation through biopsy is essential for determining the histological subtype (epithelioid, sarcomatoid, or biphasic), performing immunohistochemistry with standardized marker panels, conducting ancillary molecular testing including BAP1 loss and CDKN2A FISH, and developing an evidence-based treatment plan that matches the individual patient's disease characteristics.<ref name="pmc_vats_accuracy" /><ref name="dandell_diagnosis" />		A tissue biopsy remains the only definitive method for confirming a mesothelioma diagnosis, as no combination of imaging modalities can distinguish malignant [[Pleural Mesothelioma\|pleural mesothelioma]] from metastatic pleural disease or benign pleural conditions with sufficient certainty to guide treatment decisions. CT scanning achieves only 68% sensitivity and 78% specificity for pleural malignancy, while PET-CT improves sensitivity to approximately 95% but produces false positives from inflammatory conditions such as tuberculous pleurisy and prior talc pleurodesis.<ref name="pmc_clinical_diagnosis" /><ref name="pmc_diagnostic_approach" /> Histological confirmation through biopsy is essential for determining the histological subtype (epithelioid, sarcomatoid, or biphasic), performing immunohistochemistry with standardized marker panels, conducting ancillary molecular testing including BAP1 loss and CDKN2A FISH, and developing an evidence-based treatment plan that matches the individual patient's disease characteristics.<ref name="pmc_vats_accuracy" /><ref name="dandell_diagnosis" />

	The diagnostic pathway for suspected mesothelioma involves a hierarchy of procedures ranging from minimally invasive fluid sampling to open surgical biopsy, each with distinct accuracy profiles and clinical indications. Thoracentesis with pleural fluid cytology serves as the initial screening step but achieves only approximately 35% sensitivity for mesothelioma, significantly lower than for other pleural malignancies. CT-guided core needle biopsy provides 93% diagnostic yield when targeting visible pleural thickening, while video-assisted thoracoscopic surgery and medical thoracoscopy represent the gold standard with sensitivity exceeding 93-95% and the ability to combine diagnostic biopsy with therapeutic fluid drainage and pleurodesis in a single procedure.<ref name="pmc_diagnostic_approach" /><ref name="pmc_vats_accuracy" /><ref name="mlc_diagnosis" />		The diagnostic pathway for suspected mesothelioma involves a hierarchy of procedures ranging from minimally invasive fluid sampling to open surgical biopsy, each with distinct accuracy profiles and clinical indications. Thoracentesis with pleural fluid cytology serves as the initial screening step but achieves only approximately 35% sensitivity for mesothelioma, significantly lower than for other pleural malignancies. CT-guided core needle biopsy provides 93% diagnostic yield when targeting visible pleural thickening, while video-assisted thoracoscopic surgery and medical thoracoscopy represent the gold standard with sensitivity exceeding 93-95% and the ability to combine diagnostic biopsy with therapeutic fluid drainage and pleurodesis in a single procedure.<ref name="pmc_diagnostic_approach" /><ref name="pmc_vats_accuracy" /><ref name="mlc_diagnosis" />

MesotheliomaSupport: Create comprehensive biopsy procedures page covering thoracentesis, CT-guided biopsy, VATS, laparoscopy, mediastinoscopy, open biopsy, IHC panels, and tract seeding evidence

2026-02-20T05:08:12Z

Create comprehensive biopsy procedures page covering thoracentesis, CT-guided biopsy, VATS, laparoscopy, mediastinoscopy, open biopsy, IHC panels, and tract seeding evidence

Show changes

← Older revision		Revision as of 10:12, 6 April 2026
Line 289:		Line 289:
	<ref name="pmc_clinical_diagnosis">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5830561/ Clinical Diagnosis of Malignant Pleural Mesothelioma], National Center for Biotechnology Information (NCBI), National Library of Medicine</ref>		<ref name="pmc_clinical_diagnosis">[https://pmc.ncbi.nlm.nih.gov/articles/PMC5830561/ Clinical Diagnosis of Malignant Pleural Mesothelioma], National Center for Biotechnology Information (NCBI), National Library of Medicine</ref>
	<ref name="pmc_diagnostic_approach">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12373620/ A Diagnostic Approach to Malignant Pleural Mesothelioma], Aujayeb A, Astoul P. ''Pulmonary Therapy'' (2025)</ref>		<ref name="pmc_diagnostic_approach">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12373620/ A Diagnostic Approach to Malignant Pleural Mesothelioma], Aujayeb A, Astoul P. ''Pulmonary Therapy'' (2025)</ref>
	~~<ref name="mayo_diagnosis">[https://www.mayoclinic.org/diseases-conditions/mesothelioma/diagnosis-treatment/drc-20375028 Mesothelioma - Diagnosis and Treatment], Mayo Clinic</ref>~~
	<ref name="pmc_vats_accuracy">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12787047/ The Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Diagnosis of Pleural Mesothelioma], National Center for Biotechnology Information (NCBI)</ref>		<ref name="pmc_vats_accuracy">[https://pmc.ncbi.nlm.nih.gov/articles/PMC12787047/ The Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Diagnosis of Pleural Mesothelioma], National Center for Biotechnology Information (NCBI)</ref>
	<ref name="pmc_ihc_panel">[https://pmc.ncbi.nlm.nih.gov/articles/PMC7082260/ Application of Immunohistochemistry in Diagnosis and Management of Malignant Mesothelioma], ''Translational Lung Cancer Research'' (2020)</ref>		<ref name="pmc_ihc_panel">[https://pmc.ncbi.nlm.nih.gov/articles/PMC7082260/ Application of Immunohistochemistry in Diagnosis and Management of Malignant Mesothelioma], ''Translational Lung Cancer Research'' (2020)</ref>
	<ref name="wiley_genomic_ihc">[https://onlinelibrary.wiley.com/doi/10.1111/pin.13235 Update of Pathological Diagnosis of Pleural Mesothelioma Using Genomic-Based Morphological Techniques], ''Pathology International''</ref>		<ref name="wiley_genomic_ihc">[https://onlinelibrary.wiley.com/doi/10.1111/pin.13235 Update of Pathological Diagnosis of Pleural Mesothelioma Using Genomic-Based Morphological Techniques], ''Pathology International''</ref>
	<ref name="jtd_pleural_effusion">[https://jtd.amegroups.org/article/view/14813/html Diagnosis and Management of Malignant Pleural Effusions], ''Journal of Thoracic Disease''</ref>		<ref name="jtd_pleural_effusion">[https://jtd.amegroups.org/article/view/14813/html Diagnosis and Management of Malignant Pleural Effusions], ''Journal of Thoracic Disease''</ref>
	<ref name="academicmed_cytology">[https://www.academicmed.org/Uploads/Volume7Issue6/20.%206039.%20JAMP_R205_106-111.pdf Evaluation of Pleural Fluid Cytology and Its Role in Clinical Management], ''Journal of Academic Medicine''</ref>
	<ref name="ats_contemporary">[https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201902-189CME?download=true Contemporary Approach to the Diagnosis of Malignant Pleural Mesothelioma], ''Annals of the American Thoracic Society''</ref>		<ref name="ats_contemporary">[https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201902-189CME?download=true Contemporary Approach to the Diagnosis of Malignant Pleural Mesothelioma], ''Annals of the American Thoracic Society''</ref>
	<ref name="pmc_cytology_evaluation">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9542185/ Evaluation of Pleural Fluid Cytology for the Diagnosis of Malignant Pleural Effusion], National Center for Biotechnology Information (NCBI)</ref>		<ref name="pmc_cytology_evaluation">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9542185/ Evaluation of Pleural Fluid Cytology for the Diagnosis of Malignant Pleural Effusion], National Center for Biotechnology Information (NCBI)</ref>
Line 316:		Line 314:
	<ref name="dandell_diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Danziger & De Llano, Mesothelioma Attorneys</ref>		<ref name="dandell_diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Danziger & De Llano, Mesothelioma Attorneys</ref>
	<ref name="dandell_mesothelioma">[https://dandell.com/mesothelioma/ Mesothelioma], Danziger & De Llano, Mesothelioma Attorneys</ref>		<ref name="dandell_mesothelioma">[https://dandell.com/mesothelioma/ Mesothelioma], Danziger & De Llano, Mesothelioma Attorneys</ref>
	~~<ref name="dandell_causes">[https://dandell.com/mesothelioma-causes/ Mesothelioma Causes], Danziger & De Llano, Mesothelioma Attorneys</ref>~~
	~~<ref name="dandell_lawsuits">[https://dandell.com/mesothelioma-lawsuits/ Mesothelioma Lawsuits], Danziger & De Llano, Mesothelioma Attorneys</ref>~~
	<ref name="mlc_diagnosis">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref>		<ref name="mlc_diagnosis">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref>
	<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/ Mesothelioma Treatment], Mesothelioma Lawyer Center</ref>		<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/mesothelioma/treatment/ Mesothelioma Treatment], Mesothelioma Lawyer Center</ref>
	~~<ref name="mlc_biopsy">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/biopsy/ Mesothelioma Biopsy], Mesothelioma Lawyer Center</ref>~~
	<ref name="mesonet_biopsy">[https://mesothelioma.net/mesothelioma-biopsy/ Mesothelioma Biopsy: Types and What to Expect], Mesothelioma.net</ref>		<ref name="mesonet_biopsy">[https://mesothelioma.net/mesothelioma-biopsy/ Mesothelioma Biopsy: Types and What to Expect], Mesothelioma.net</ref>
	<ref name="mesonet_diagnosis">[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>		<ref name="mesonet_diagnosis">[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref>